Principles of drug administration in renal insufficiency

Clinical Pharmacokinetics

Volumn 32, Issue 1, 1997, Pages 30-57

  Lam, Y W Francis ^b   Banerji, Shireen ^b   Hatfield, Catherine ^b   Talbert, Robert L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMIODARONE; AMPHOTERICIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CIBENZOLINE; CIMETIDINE; CLOXACILLIN; CREATININE; DICLOXACILLIN; DIGOXIN; DIHYDROCODEINE; FOLIC ACID; FOSCARNET; GENTAMICIN; IRON; LITHIUM; METHOTREXATE; METICILLIN; PHOSPHATE BINDING AGENT; PROCAINAMIDE; QUINIDINE; RECOMBINANT ERYTHROPOIETIN; THIAZIDE DIURETIC AGENT; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN; VITAMIN D;

CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE CLEARANCE; CYSTIC FIBROSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG USE; GLOMERULUS FILTRATION; HEALTH CARE COST; HEMODIALYSIS; HEMOFILTRATION; HEMOPERFUSION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY METABOLISM; KIDNEY PARENCHYMA; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VOMITING;

EID: 0031015510     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732010-00002     Document Type: Review

References (118)

1. Eberhardt MS, Wagener DK, Herman WH, et al. Trends in renal disease morbidity and mortality in the United States, 1979 to 1990. Am J Kidney Dis 1995; 26 (2): 308-20
2. Kochanek KD, Hudson BL. Advance report of final mortality statistics, 1992. Monthly Vital Statistics Report, National Center for Health Statistics, Centers for Disease Control and Prevention 1995 Mar; 43 (6 Suppl.): 1-76
3. US Renal Disease System: USRDS 1993 Annual Data Report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disorders, 1993
4. Schusterman N, Strom BL, Murray TG, et al. Risk factors and outcome of hospital-acquired acute renal insufficiency: clinical epidemiology study. Am J Med 1987; 83: 65-71
5. Ferguson R, Morrissey E. Risk factors for end-stage renal disease among minorities. Transplant Proc 1993 Aug; 24 (4): 2415-20
6. Smith SR, Svetkey LP, Dennis VW. Racial differences in renal disease. Kidney Int 1991; 40: 815-22
7. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996 Jun; 334: 13-8
8. Cantu TG, Ellerheck ED, Yun SW, et al. Drug prescribing for patients with changing renal function. Am J Hosp Pharm 1992; 49: 2944-8
9. Manasse HR. Medication use in an imperfect world: drug misadventuringas an issue of public policy (Pt 1). Am J Hosp Pharm 1989; 46: 929-44
10. Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1995; 155: 1949-56
11. Rind DM, Safran C, Phillips RS, et al. Effect of computer-based alerts on the treatment and outcomes of hospitalized patients. Arch Intern Med 1994; 154: 1511-7
12. The effect of computer-based reminders on the management of hospitalized patients with worsening renal function. Proc Annu Symp Comput Appl Med Care 1991: 28-32
13. Taylor JW, McLean AJ, Leonard RG, et al. Initial experience of clinical pharmacology and clinical pharmacy interactions in a clinical pharmacokinetics consultation service. J Clin Pharmacol 1979; 19: 1-7
14. Goldberg DE, Baardsgaard G, Johnson MT, et al. Computer-based program for identifying medication orders requiring dosage modification based on renal function. Am J Hosp Pharm 1991; 48: 1965-9
15. Bjornson DC, Hiner WO, Potyk RP, et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm 1993; 50: 1875-84
16. Morton TA, Talbert RL. Reduction in drug charges in hospitalized patients through clinical pharmacy interventions. Pharmacotherapy 1991; 11: 99
17. Soumerai SB, Lipton HL. Computer-based drug-utilization review: risk, benefit, or boondoggle? N Engl J Med 1995; 332: 1641-5
18. Comstock TJ. Quantification of renal function. In: Dipiro JT, Talbert RL, Hayes PE, et al., editors. Pharmacotherapy: a pathophysiologic basis. 3nd ed. Norwalk (CT): Appleton-Lange. Inc., 1996: 867-85
19. Matzke GR, Frey RF. Drug therapy individualization for patients with renal insufficiency. In: Dipiro JT, Talbert RL, Hayes PE, et al., editors. Pharmacothcrapy: a pathophysiologic basis. 2nd ed. Norwalk (CT): Appleton-Lange, Inc., 1966: 1083-103
20. Matzke GR, Millikin SP. Influence of renal function and dialysis on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics, Inc., 1992: 8.1-8.49
21. Mawer CE, Knowles BR, Lucas SB, et al. Computer-assisted prescribing of kanamycin for patients with renal insufficincy. Lancet 1972; I: 12-5
22. Jelliffe RW. Creatinine clearances: bedside estimate. Ann Intern Med 1973; 79: 604-5
23. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton (IL): Drug Intelligence Publications, 1975: 162
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
25. Hull JK, Hak LJ, Koch GC, et al. Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther 1981; 29: 516-21
26. Schwartz GJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104: 849-54
27. Schwartz GJ. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-63
28. Dechaux M, Gonzalez G, Broyer M. Plasma creatinine, and clearance and urinary excretion of creatinine in children. Arch Fr Pediatr 1978; 35: 53-62
29. Tozer TN. Nomogram for modification of dosage regimens in patients with chronic renal impairment. J Pharmacokinet Biopharm 1974; 2: 13-28
30. Jelliffe RW, Jeliffe SW. A computer program for estimation of creatinine clearance from unstable serum creatinine concentration. Math Biosci 1972; 14: 17-24
31. Chiou WL, Hsu FH. A new simple rapid method to monitor renal function based on pharmacokinetic considerations of endogenous creatinine. Res Comm Chem Path Pharmacol 1975; 10: 15
32. Brater DC. Handbook of drug use in patients with renal disease. 2nd ed. Lancaster: Improved Therapeutics, 1982
33. DeSanto NG, Anastasio P, Loguercio C, et al. Creatinine clearance: an inadequate marker of renal filtration in patients with early posthepatitic cirrhosis (Child A) without fluid retention and muscle wasting. Nephron 1995; 70: 421-4
34. DeSanto NG, Anastasio P, Cirrillo M, et al. Sequential analysis of variation in glomerular filtration rate to calculate the haemodynamic response to a meat meal. Nephrol Dial Transplant 1995; 10: 1629-36
35. Lesar TS, et al. Gentamicin dosage errors with four commonly used nomograms. JAMA 1982; 248: 1190-3
36. Zokufa HZ, et al. Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients. Pharmacotherapy 1989; 9: 10
37. Guay DR, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993; 33: 918-22
38. Davis BD. Mechanism of the bactericidal action of the aminoglycosides. Microbiol Rev 1987; 51: 341-50
39. Zhanel GG, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP 1991; 25: 153-62
40. Sloan RW. Principles of drug therapy in geriatric patients. Am Fam Physician 1992; 45: 2709-18
41. Skaer TL. Drug dosing considerations in the pediatric patient. Clin Ther 1991; 13: 526-44
42. Arant BS. Developmental patterns of renal function maturation compared in the human neonate. J Pediatr 1978; 92: 705-12
43. Crom WR. Pharmacokinetics in the child. Environ Health Perspect 1994; 102 Suppl. 11: 111-8
44. Linday LA. Developmental changes in renal tubular function. J Adolesc Health 1994; 15: 648-53
45. Passwell JH, Modan M, Brish M, et al. Fractional excretion of uric acid in infancy and childhood: index of tubular maturation. Arch Dis Childhood 1974; 49: 878-82
46. Milsap RL, Jusko WJ. Pharmacokinetics in the infant. Environ Health Perspect 1994; 102 Suppl. 11: 107-10
47. Rodman JH. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J Adolesc Health 1994; 15: 654-62
48. Routledge PA. Pharmacokinetics in children. J Antimicrob Chemother 1994; 34 Suppl. A: 19-24
49. Chutka DS, Evans JM, Fleming KC, et al. Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70: 685-93
50. Mayersohn M. Pharmacokinetics in the elderly. Environ Health Perspect 1994; 102 Suppl. 11: 119-24
51. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-85
52. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-63
53. Swift CG. Pharmacokinetics and prescribing in the elderly. J Antimicrob Chemother 1994; 34 Suppl. A: 25-32
54. Friedman SA, Faizner AE, Rosen H, et al. Functional defects in the ageing kidney. Ann Intern Med 1972; 76: 41-5
55. Dontas AS, Papanayiotou P, Markitos SG, et al. the effects of bacteriuria on renal function patterns in old age. Clin Sci 1968; 34: 73-81
56. Rius F, Pizarro E, Salinas I, et al. Age as a determinant of glomerular filtration rate in non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1995; 10: 1644-7
57. Winters ME. Basic clinical pharmacokinetics. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1994: 198-235
58. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 1994; 15: 619-29
59. Davison JM, Noble MCB. Serial changes in 24 hour creatinine clearance during nornal menstrual cycle annd the first trimester of pregnancy. Br J Obstet Gynecol 1981; 88: 10-7
60. Nafziger AN, Schwartzman MS, Bertino JS. Absence of tobramycin pharmacokinetics and creatinine clearance variation during the menstrual cycle: implied absence of variation in flumerular filtration rate. J Clin Pharmacol 1989; 29: 757-63
61. Gambertoglio JG. Effects of renal disease: altered pharmacokinetics. In: Benet LZ, Massoud N, Gambertoglio JG, editors. Pharmacokinetic basis for drug treatment. New York: Raven, 1984: 149-71
62. Bianchetti G, Graziani G, Brancacci D, et al. Pharmacokinetics and effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976; 1: 373-84
63. Balant LP, Dayer P, Fabre J. Consequenes of renal insufficiency on the hepatic clearance of some drugs. Int J Clin Pharmacol Res 1983; 3: 459-74
64. Barnes JN, Williams AJ, Tomson MJF, et al. Dihydrocodeine in renal insufficiency: further evidence for an important role of the kidney in the handling of ovoid drugs. BMJ 1985; 290: 740-2
65. Gibson TP, Giacomini KM, Briggs WA, et al. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther 1980; 27: 665-70
66. Barnes JN, Goodwill FJ. Dihydrocodeine narcosis in renal insufficiency. BMJ 1983; 286: 438
67. Redfern N. Dihydrocodeine overdose treated with naloxone infusion. BMJ 1983; 287: 751-2
68. Plaisance KI, Drusano GL, Forrest A, et al. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1990; 34: 1031-4
69. Guay DRP, Matzke GR, Bockbrader HN, et al. Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. Clin Pharm 1983; 2: 157-62
70. Jusko WJ, Szefier SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol 1974; 14: 525-35
71. Pritchard JR, O'Neill PJ, Affirme MB, et al. Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding. Clin Pharmacol Ther 1983; 34: 681-8
72. Matzke GR, Sawchuk RJ. Protein binding of phenytoin, p-hydroxyphenytoin (HPPH) and HPPH glucuronide in patients with end-stage renal disease. Drug Intell Clin Pharm 1983; 1: 443-4
73. Vanholder R, Van Landschoot N, De Smet R, et al. Drug protein binding in chronic renal insufficiency: evaluation of nine drugs. Kidney Int 1988; 33: 996-1004
74. Haughey DB, Kraft CJ, Matzke GR, et al. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 1985; 5: 35-9
75. Palterson SE, Cohn VH. Hepatic drug metabolism in rats with experimental long-term renal insufficiency. Biochem Pharmacol 1984; 35: 711-6
76. Gibson TP. Renal disease and drug metabolism. Am J Kidney Dis 1986; 8: 7-17
77. Fillastre JP, Leroy A, Moulin B, et al. Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother 1990; 26 Suppl. B: 51-60
78. Ahmed JH, Grant AC, Rodger RSC, et al. Inhibitory effect of uremia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991; 32: 57-72
79. Lam YWF, Flaherty JF, Yumena L, et al. Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1995; 36: 157-63
80. Halstenson CE, Opsahl JA, Schwenk MH, et al. Disposition of roxithromycin in patients with normal and severely impaired renal function. Antimicorb Agents Chemother 1990; 34: 385-9
81. Kroboth PD, McNeil MA, Kreeger A, et al. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch Intern Med 1983; 143: 1263-5
82. Teunissen MWE, Kampf D, Roots I, et Al. AntipyrinE metabolite formation and excretion in patients with chronic renal insufficiency. Eur J Clin Pharmacol 1985; 28: 589-95
83. Terao N, Shen DD. Reduced extraction of 1-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther 1985; 233: 277-84
84. Anders MW. Metabolism of drugs by the kidney. Kidney Int 1980; 18: 636-47
85. DeLuca HF, Schnoes HK. Metabolism and mechanism of action of vitamin D. Ann Rev Biochem 1976; 45: 631-66
86. Duckworth WC. Insulin degradation: mechanisms, products and significance. Endocr Rev 1988; 9: 319-45
87. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984; 27: 351-7
88. Osborne R, Joel SP, Slevin ML. Morphine intoxication in renal insufficiency: the role of morphine-6-glucuronide. BMJ 1986; 292: 1548-9
89. Milne RW, Nation RL, Somogyi AA, et al. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 1992; 34: 53-9
90. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130-8
91. Gloff CA, Benet LZ. Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats. J Pharmacokinet Biopharm 1989; 17: 169-77
92. Miura K, Goldstein RS, Morgan DC, et al. Age-related differences in susceptibility to renal ischemia in rats. Toxicol Appl Pharmacol 1987; 86: 284-96
93. Fleck C, Heller J. Age-dependent differences in the effect of ischemia on the rat kidney: prevention of the postischemic damage by different drugs. Exp Toxicol Pathol 1993; 45: 381-7
94. Maiza A, Waldek S, Ballardie FW, et al. Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide. Nephron 1992; 60: 12-6
95. Reidenberg MM, Camacho M, Kluger J, et al. Aging and renal clearance of procainamide and acetylprocainamide. Clin Pharmacol Ther 1980; 28: 732-5
96. Lin JH, Chremos AN, Yek KC, et al. Effect of age and chronic renal insufficiency on the urinary excretion and kinetics of famotidine in man. Eur J Clin Pharmacol 1988; 34: 41-6
97. Hori R, Okumura K, Kamiya A, et al. Ampicillin and cephalexin in renal insufficiency. Clin Pharmacol Ther 1983; 34: 792-8
98. Lam YWF, Boyd RA, Chin SK, et al. Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol 1991; 31: 429-32
99. Hardman JG, Limbird LE, Molinoff PB, et al. editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1712-91
100. Lee CC, Marbury TC. Drug therapy in patients undergoing haemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 1984; 9: 42-66
101. Paton TW, Cornish WR, Manuel MA, et al. Drug therapy in patients undergoing peritoneal dialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 1985; 10: 404-26
102. Bastani B, Spyker DA, Minocha A, et al. In vivo comparison of three different hemodialysis membranes for vancomycin clearance: cuprophane, cellulose acetate, and polyacrylonitrile. Dial Transplant 1988; 17: 527-8
103. Lanese DM, Alfrey PS, Molitoas BA. Markedly increased clearance of vancomycin dyring hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35: 1409-12
104. Torras J, Cao C, Rivas MC, et al. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991; 36: 35-41
105. Halstenson CE, Berkseth RO, Mann HJ, et al. Aminoglycoside redistribution phenomenon after hemodialysis: netilmicin and tobramycin. Int J Clin Pharmaocl Ther Toxicol 1987; 25: 50-5
106. Bauer LA. Rebound gentamicin levels after hemodialysis. Ther Drug Monitor 1982; 4: 99-101
107. Keller F, Offerman G, Scholle J. Kinetics of the redistribution phenomenon after extracorporeal elimination. Int J Artif Organs 1984; 7: 181-8
108. Paton TW. Drug therapy in patients undergoing peritoneal dialysis: clinical pharmacokientic considerations. Clin Pharmacokinet 1985; 10: 404-26
109. Maher JP. Influence of continuous ambulatory peritoneal dialysis on elimination of drugs. Perit Dial Bull 1987; 7: 159-67
110. Keane WF, Everett ED, Golper TA, et al. Peritoneal dialysis-related peritonitis: treatment recommendations. 1993 update. Peril Dial Int 1993; 13: 14-28
111. Lau AH, Kronfol NO, Jabar N, et al. Determinants of drug removal by continuous arteriovenous hemofiltration. Drug Intell Clin Pharm 1986; 20: 467
112. Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. Trans Am Soc Artif Int Organs 1987; 33: 300-3
113. Bressolle F, Kinowski JM, de la Coussaye JM, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994; 26: 457-71
114. Reetze P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokientic and therapeutic considerations. Clin Pharmacokinet 1993; 24: 362-79
115. Barr JT, Schumacher GE. Outcomes assessment of therapeutic drug monitoring: system and patient considerations. In: Schumacher GE, editor. Therapeutic drug monitoring. Norwalk (CT): Appleton and Lange, 1995: 191-236
116. Bootman JL, Wertheimer AI, Zaske D, et al. Individualized gentamicin dosage regimens in burn patients with Gram-negative septicema: a cost-benefit analysis. J Pharm Sci 1979; 68: 267-72
117. Burton ME, Ash CL, Hill DP, et al. A controlled trial of the cost benefit of a computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49: 1887-93
118. Destache CJ, Meyer SM, Bittner MJ, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990; 12: 419-27